A Phase 1/2, Open-Label, Multicenter, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics/Pharmacodynamics, and Preliminary Efficacy of ISM3412 in Participants With Locally Advanced/Metastatic Solid Tumors
This study is testing a new experimental medication called ISM3412 for people with advanced solid tumor cancers. Researchers want to find out the safest and most effective dose of this new drug to help patients.
You might be able to join if you are 18 or older, have advanced cancer with a specific genetic feature called MTAP deletion, and standard treatments are no longer working or available. Your overall health must also be good enough to support daily activities.
During the study, you will receive the experimental medication ISM3412, and doctors will carefully monitor your health and safety. The study starts by finding the right dose in Part 1 and then tests that chosen dose more closely in Part 2.
This study is currently recruiting patients at medical locations in Denver, Colorado, New Haven, Connecticut, and Indianapolis, Indiana.
- 1Testing a brand-new experimental cancer drug called ISM3412
- 2Open to adults with advanced solid tumors and an MTAP genetic deletion
- 3Currently actively recruiting at multiple locations in the United States
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.